financetom
Business
financetom
/
Business
/
ASP Isotopes Subsidiary Launches $64.3 Million Private Offering of Convertible Notes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ASP Isotopes Subsidiary Launches $64.3 Million Private Offering of Convertible Notes
Nov 7, 2025 7:24 AM

09:56 AM EST, 11/07/2025 (MT Newswires) -- ASP Isotopes ( ASPI ) subsidiary Quantum Leap energy said Friday it launched a $64.3 million private offering of convertible notes.

The notes will mature on the fifth anniversary of the initial closing, unless converted in accordance with their terms, Quantum Leap said.

The company said it intends to use the net proceeds from the offering to build and develop laser enrichment production facilities, as well as for general corporate purposes.

The issuance of the notes will result in the automatic conversion of Quantum Leap's outstanding convertible promissory notes issued in March 2024 and June 2024, pursuant to their terms, the company said.

Price: 7.53, Change: -0.13, Percent Change: -1.70

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SLB beats estimates for third-quarter profit on strong North America demand
SLB beats estimates for third-quarter profit on strong North America demand
Oct 17, 2025
(Reuters) -SLB beat Wall Street estimates for third-quarter profit on Friday, helped by strong demand for its oilfield equipment and services in North America. The company reported an adjusted profit of 69 cents per share for the quarter ended September 30, compared with analysts' estimate of 66 cents, according to data compiled by LSEG. Quarterly revenue from its North America...
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Oct 17, 2025
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ( XRTX ) (“XORTX” or the “Company”) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a binding term sheet (the “Term Sheet”) to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems...
Form 8.3 - Unite Group
Form 8.3 - Unite Group
Oct 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: CCLA Investment Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Oct 17, 2025
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved